After meeting with the Food and Drug Administration, Sage Therapeutics said Wednesday that it will start three new studies with the aim of getting its experimental antidepressant pill approved in 2022, while looking to cut costs to control its spending.

This is Sage’s backup plan for its most important depression drug called zuranolone, or SAGE-217, following the failure of a Phase 3 clinical trial in early December. The new studies will cover three different uses of the drug: in postpartum depression; as a “rapid response treatment” when added to traditional antidepressants, known as SSRIs; and as a treatment to help patients undergoing an episode of depression.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy